Medicine and Dentistry
Cabozantinib
66%
Cancer
33%
Cancer Cell
33%
Clear Cell Renal Cell Carcinoma
100%
Clinical Trial
66%
Combination Therapy
33%
Diseases
33%
Everolimus
33%
Glutaminase
100%
Glutamine
66%
Metabolism
33%
Metabolomics
33%
Monotherapy
33%
Neoplasm
33%
Nivolumab
33%
Protein Tyrosine Kinase
33%
Therapeutic Agent
33%
Tumor Cell
66%
Tyrosine-Kinase Inhibitor
33%
Pharmacology, Toxicology and Pharmaceutical Science
Cabozantinib
66%
Clinical Trial
66%
Combination Therapy
33%
Diseases
33%
Everolimus
33%
Glutaminase
100%
Glutamine
66%
Malignant Neoplasm
33%
Monotherapy
33%
Neoplasm
100%
Nivolumab
33%
Protein Tyrosine Kinase
33%
Protein Tyrosine Kinase Inhibitor
33%
Renal Cell Carcinoma
100%